President Donald Trump recently met with many of the nation's top pharmaceutical company executives, with meeting attendees giving a clearer picture on what the conversation entailed, according to the Washington Post.
Here are four things to know:
1. The Washington Post reports executives said the president did not delve into "government intervention on drug pricing" when "behind closed doors."
2. In an investor call, Kenilworth, N.J.-based Merck Chief Executive Kenneth Frazier said the meeting's dialogue did not drive him to believe secretarial negotiations will tackle the issue of spiraling drug prices. Mr. Frazier said, "We know there'll be bills that are introduced in Congress calling for that. But I think the fact of the matter is ... that is not perceived to be the solution to the problem."
3. Thousand Oaks, Calif.-based Amgen Chief Executive Robert Bradway said the conversation did not go into specifics concerning HHS' role in efforts rein in drug prices.
4. The conversation did touch on patients' ability to afford drugs at pharmacies, noted David Ricks, chief executive of Indianapolis-based Eli Lilly. Mr. Ricks said the following in an earnings call following the meeting, "We did not get into elaborate policy detail in terms of the U.S. pricing environment."